Pfizer Ltd - 500680 - Corporate Action-Board approves Dividend
Pfizer's board recommended a final dividend of ₹75 per share (750%) for the financial year ended March 31, 2026. The Record Date for determining dividend entitlement is July 17, 2026.
May 12 2026 20:05:00
Pfizer Ltd - 500680 - Board Meeting Intimation for Board Meeting To Consider And Approve The Financial Results For The Quarter And Year Ended March 31, 2026.
Pfizer's Board is scheduled to meet on May 12, 2026, to consider and approve the financial results for the fourth quarter and full fiscal year ending March 31, 2026. The meeting will also include discussion on a potential dividend recommendation for the concluded fiscal year.
May 05 2026 22:05:00
Pfizer Limited
Pfizer board will meet on May 12, 2026, to consider its audited standalone yearly financial results for the period ended March 2026. The agenda also includes the recommendation of a final dividend.
May 05 2026 22:05:00
Pfizer Limited
Pfizer board will meet on May 12, 2026, to consider its audited standalone yearly financial results for the period ended March 2026. The agenda also includes the recommendation of a final dividend.
May 05 2026 21:05:00
Pfizer Limited
Pfizer board will meet on May 12, 2026, to consider its audited standalone yearly financial results for the period ended March 2026. The agenda also includes the recommendation of a final dividend.
May 05 2026 21:05:00
US market today: Pfizer posts strong first-quarter, sees boost from recent legal wins
Pfizer reported better-than-expected first-quarter 2026 earnings, with revenues of $14.5 billion and adjusted diluted EPS of $0.75, surpassing analyst estimates. The company reaffirmed its full-year 2026 guidance and demonstrated significant operational revenue growth from launched and acquired products, which largely offset declines in COVID-19 vaccine and treatment sales. Furthermore, Pfizer recently secured a crucial patent extension for its heart drug Vyndamax until 2031 and benefited from a favorable European court ruling regarding COVID-19 vaccine contracts, reinforcing future revenue streams.
May 05 2026 21:05:00
Pfizer among 6 stocks showing bullish RSI upswing
Pfizer's stock has shown a bullish Relative Strength Index (RSI) upswing, indicating strengthening price momentum as its RSI value crossed above 50, according to data from StockEdge.com.
Apr 29 2026 08:04:00
Pfizer Limited
Pfizer Limited clarified its XBRL submission for Q2 & H1 FY26 financial results. The company revised the reporting type to 'Second Quarter' from 'Half Year' following advice from the National Stock Exchange of India on November 28, 2025.
Apr 13 2026 16:04:00
Read More